Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-659 ADME study in advanced solid tumors and lymphomas
NCT03338881Phase 1Withdrawn
- Sponsor
- Calithera Biosciences
- Start
- May 2018
- Primary completion
- May 2019
01
Overview
Phase 1, open-label trial of mivavotinib in malignant solid tumor and lymphoma, sponsored by Calithera Biosciences. Primary endpoint: Maximum Observed Plasma Concentration for TAK-659 at 240 hours. Planned start May 2018; status: withdrawn.
02
Drugs
mivavotinib
03
Conditions
malignant solid tumorlymphoma
Beyond the preview
Go deeper on NCT03338881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03338881.